Posted in | News | Nanomedicine | Nanobusiness

BioForce Nanosciences to Take Nano eNabler Molecular Printer on Asian Roadshow in May

BioForce Nanosciences, Inc., a wholly owned subsidiary of BioForce Nanosciences Holdings, Inc., announces that its flagship product, the Nano eNabler molecular printer, is on an Asian road show through May. Earlier this month, the traveling system ventured to India. From Mumbai to Roorkee-seven cities in 10 days-the device is being demonstrated to potential customers. This is possible because of BioForce Nanosciences' strong relationship with an international distributor network serving customers overseas. The traveling unit will visit additional sites in Thailand (March), Japan (April), and finish up in Korea (May).

At each location, BioForce staff will demonstrate how the system can print with precision and speed; the software and the print heads used with the Nano eNabler system; and the research applications for which the molecular printer is most commonly being utilized by researchers, such as cell biology for cancer research, brain function, or virus detection.

"BioForce is building on the 2006 international response to our Nano eNabler system," says Kerry Frey, BioForce's chief operating officer. "In 2007, BioForce will be cementing our existing distributor relationships, and expanding our distributor network."

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.